Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bexsero in Infants and Children
NCT01339923Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease (7 arms), sponsored by Novartis. Primary endpoint: Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers >= 4 or hSBA Titers >= 5 (Strain M10713). Started Apr 2011; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01339923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01339923.